Listed clinical trials group Hvivo has announced it will remove its shares from the Irish market later this year.
Hvivo was formed when the group’s chairman Cathal Friel reversed his pharma services business of the same name into Dublin-listed drug clinical trials manager Venn Life Sciences.Nursing home fees: can I claim tax relief on behalf of my dad? The cancellation will also remove certain costs, complexities and duplication that comes from administering two listing regimes and will have no impact on Hvivo’s ordinary shares which will continue to trade on AIM under the ticker “HVO”.
Mr Friel sold his remaining shares in the group last month “to satisfy institutional demand” after that capital markets day, the company said, raising £6.14 million for the 3.1 per cent stake at 29 pence each.